New drug duo aims to make inoperable sinus cancer removable
NCT ID NCT07522879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted antibody-drug conjugate) and epirubicin (a standard chemo)—in 40 people with EGFR-positive, recurrent sinonasal adenoid cystic carcinoma that cannot be surgically removed. The goal is to shrink the tumor enough to allow radical surgery. The study measures how many patients respond and whether they can then undergo successful tumor removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Becotatug vedotin (MRG003) combined with epirubicin
What this could lead to
If successful, this combination could shrink tumors enough to allow surgical removal, potentially improving disease control and survival for a rare cancer with few options.
What could go wrong
This is a small, early-phase trial (40 people) with no control group. The drugs may cause side effects like nerve damage or heart toxicity, and the response rate may be too low to enable surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital of Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••